What the trial was testing
The IDEAL Strategy enrolled 1,895 patients with lupus. The study was sponsored by University of Alabama at Birmingham and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
83% of patients felt their actual role in treatment decisions matched what they preferred.
The Lancet. Rheumatology · 2026 · NCT03735238
These findings — that felt their actual role in treatment decisions matched their preferred role — were published in the The Lancet. Rheumatology and represent the headline result of the study.
Researchers tracked outcomes across 1,895 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with lupus, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This tool helps you understand your lupus treatment options and have better conversations with your rheumatologist. It's designed to reduce confusion and let you play the role you want in deciding your care. The app (ManageMyLupus) is free and available now — ask your doctor if it's right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open lupus trials
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).